Floatz logo

Ribociclib

Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
59/ 100

Competitive context

848 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

Ribociclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
HR+/HER2- Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →